Booz Allen Hamilton
BAH
$62.76
-0.63%
Booz Allen Hamilton Holding Corporation provides technology solutions in artificial intelligence, cybersecurity, and related fields, primarily serving U.S. federal government agencies, commercial clients, and select international customers. As a leading defense and consulting contractor, it distinguishes itself through deep expertise in mission-critical digital transformation and national security. The current investor narrative centers on the Pentagon's aggressive pivot toward AI-driven autonomous systems, which is expected to create high-margin revenue streams for the company, though recent revenue declines and a sharp stock price drop have sparked debate about near-term growth sustainability.…
BAH
Booz Allen Hamilton
$62.76
Related headlines
BAH 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Booz Allen Hamilton's 12-month outlook, with a consensus price target around $81.59 and implied upside of +30.0% versus the current price.
Average Target
$81.59
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$50 - $82
Analyst target range
Insufficient analyst coverage available. Only 6 analysts cover the stock, and the consensus ratings are predominantly Hold/Neutral with a Sell from Goldman Sachs and Underweight from JP Morgan. The average EPS estimate for the current fiscal year is $7.61, with a range of $7.16 to $7.92. Revenue estimates average $12.32 billion, with a tight range of $12.32-$12.32 billion, indicating low dispersion. The lack of a clear consensus target price and the predominance of neutral-to-bearish ratings suggest limited conviction in a near-term recovery. Limited coverage typically leads to higher volatility and less efficient price discovery, which is consistent with the stock's recent sharp decline.
Drowning in data?
Find the real signal!
BAH Technical Analysis
The stock is in a sustained downtrend, with a 1-year price change of -41.7% and currently trading at 52.3% of its 52-week range (close to the 52-week low of $59.5). This positioning near the low end suggests the market is pricing in significant fundamental deterioration, though it could also represent a value opportunity if the sell-off is overdone. The current price of $62.76 is well below the 52-week high of $120.05, indicating persistent selling pressure. Short-term momentum is sharply negative, with 1-month and 3-month price changes of -18.8% and -19.7%, respectively, accelerating the longer-term downtrend. The stock's relative strength versus the S&P 500 is deeply negative across all timeframes (1-month relative strength of -22.9%), confirming broad-based underperformance. The 52-week low of $59.5 provides immediate support, while resistance lies at the 52-week high of $120.05. A breakdown below $59.5 would signal further downside, while a recovery above recent highs would require a fundamental catalyst. The beta of 0.36 indicates the stock is significantly less volatile than the market, meaning the current decline is driven by company-specific factors rather than broad market moves.
Beta
0.36
0.36x market volatility
Max Drawdown
-48.5%
Largest decline past year
52-Week Range
$60-$120
Price range past year
Annual Return
-41.7%
Cumulative gain past year
| Period | BAH Return | S&P 500 |
|---|---|---|
| 1m | -18.8% | +1.8% |
| 3m | -19.7% | +10.0% |
| 6m | -34.7% | +8.8% |
| 1y | -41.7% | +21.1% |
| ytd | -26.1% | +10.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BAH Fundamental Analysis
Revenue has been declining, with the most recent quarter (Q3 FY2026) reporting $2.62 billion, down 10.2% year-over-year from $2.92 billion in the prior-year quarter. The multi-quarter trend shows deceleration: Q2 FY2026 revenue was $2.89 billion (down from $3.15 billion a year ago), and Q1 FY2026 revenue was $2.92 billion (down from $2.94 billion). Revenue segments indicate a shift toward cost-reimbursable contracts ($1.52 billion) versus fixed-price ($521 million) and time-and-materials ($584 million), which may pressure margins. The company remains profitable, with net income of $200 million in Q3 FY2026 and a net margin of 7.6%. Gross margin was 51.9%, down from 55.2% in the prior-year quarter, indicating margin compression. Operating margin of 9.8% is stable but below the 10.0% level seen a year ago, suggesting cost pressures. The balance sheet shows a debt-to-equity ratio of 3.73, indicating high leverage, but free cash flow generation remains strong at $933 million TTM. The current ratio of 1.78x provides adequate liquidity, and ROE of 77% is exceptionally high, though partly driven by leverage. The company generated $261 million in operating cash flow in Q3, sufficient to cover capital expenditures of $13 million and dividends of $67 million, with $248 million in free cash flow.
Quarterly Revenue
$2.6B
2025-12
Revenue YoY Growth
-10.19%
YoY Comparison
Gross Margin
51.95%
Latest Quarter
Free Cash Flow
$933437000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BAH Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 11.3x, while the forward P/E is 9.1x, implying the market expects earnings growth over the next year. The gap between trailing and forward multiples suggests improving profitability ahead. Compared to the industry average (not provided), the stock's P/E of 11.3x appears low relative to the broader market, but given the revenue decline and margin compression, the discount may be warranted. Historically, the trailing P/E has ranged from 11.3x (current) to 37.8x over the past two years, placing it near the bottom of its historical band. This suggests the market is pricing in pessimistic expectations, potentially creating a value opportunity if fundamentals stabilize. The P/S ratio of 0.86x is also near historical lows, reinforcing the valuation compression.
PE
11.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -45x~111x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.5x
Enterprise Value Multiple
